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Abstract. The diagnosis of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense relies on
an initial serologic screening with the card agglutination test for trypanosomiasis (CATT) for T. b. gambiense, followed
by parasitologic confirmation in most endemic areas. Unfortunately, field parasitologic methods lack sensitivity and the
management of serologically suspected individuals (i.e., individuals with a positive CATT result but negative parasitol-
ogy) remains controversial. In Kajo-Keji County in southern Sudan, we prospectively collected sociodemographic and
laboratory data of a cohort of 2,274 serologically suspected individuals. Thirty-three percent (n  749) attended at least
one follow-up visit and HAT was confirmed in 64 (9%) cases. Individuals with lower initial CATT-plasma (CATT-P)
end-dilution titers had lowest risks (10.4 and 13.8/100 person-years for 1:4 and 1:8 titers, respectively) that significantly
increased for higher dilutions: relative risks  5.1 (95% confidence interval [CI]  2.6–9.5) and 4.6 (95% CI  2.8–9.8)
for 1:16 and 1:32 titers, respectively. The cumulative yearly risk was also high (76%) in individuals found with 11–20 cells
in the cerebrospinal fluid, but this involved only eight patients. Adjustment for potential confounders did not affect the
results. In conclusion, treatment with pentamidine should be considered for all serologically suspected individuals with
a CATT-P end-dilution titer  1:16 in areas of a moderate to high prevalence of HAT.
INTRODUCTION
Field diagnosis of human African trypanosomiasis (HAT)
due to Trypanosoma brucei gambiense relies on the initial
screening with the card agglutination trypanosomiasis test
(CATT/T. b. gambiense) in most endemic areas. The CATT/
T. b. gambiense is a cheap, quick, and practical serologic test
that has been widely used since it was developed in 1978.
1 It
is a highly sensitive test when applied on undiluted whole
blood (CATT-WB).
2 Despite its good specificity, the positive
predictive value (PPV) of the CATT-WB is limited because
the test is used for mass screening of populations in which the
prevalence of HAT rarely exceeds 5%.
2,3 The specificity of
the CATT can be further improved when performed on
plasma (CATT-P) or serum diluted to 1:4,
4 but this is still
insufficient. Confirmatory diagnosis thus relies on the finding
of trypanosomes in the lymph nodes, blood, or cerebrospinal
fluid (CSF). However, despite the use of concentration meth-
ods to detect trypanosomes in the blood or CSF, the field
parasitologic methods have a limited sensitivity and fail to
detect all infected individuals.
5,6
In Kajo-Keji County in southern Sudan, Médecins Sans
Frontières has been conducting since June 2000 a sleeping
sickness control program that relies on the systematic screen-
ing of the entire county population and treatment of all in-
fected patients. The main objective of the program is to de-
crease the prevalence of HAT to less than 0.5% in all villages.
Individuals with a positive CATT-P titer 1:4 without para-
sitologic confirmation are considered as serologically sus-
pected and are followed-up for one year. However, the effi-
ciency of this strategy remains controversial, particularly in
regions such as southern Sudan where follow-up is difficult
because of long distances, lack of transport, and population
movements. In such a setting, the determination of a CATT-P
dilution titer above which individuals are likely to have the
disease would allow the treatment of these infected individu-
als at an earlier stage and avoid the risk of losing these pa-
tients during follow-up. Moreover, with the treatment of a
higher proportion of infected individuals who are the main
reservoir of T. b. gambiense, control of the disease may be
accelerated.
The few published studies addressing this question have led
to controversial results. Of 86 serologically suspected indi-
viduals (CATT-P titer 1/4) followed in Angola, Simarro and
others found that 52% of the individuals with a CATT end
titer 1/16 were diagnosed with HAT during follow-up, but
none of the individuals with lower CATT end-titers were di-
agnosed.
7 These investigators recommended treatment with
pentamidine of all serologically suspected individuals with a
CATT end titer 1/16 in this region. Conversely, Garcia and
others found only one patient with HAT during a two-year
longitudinal follow-up of 77 serologically suspected individu-
als in a low prevalence area of Côte d’Ivoire.
8 However, in the
latter study, the CATT was performed on undiluted plasma
and on blood with a maximum dilution of 1:4.
In this study, we retrospectively analyzed the initial
CATT-P end-dilution titer and other biologic parameters as
possible determinants of outcome in a large cohort of sero-
logically suspected individuals followed-up for one year in
Kajo-Keji County in southern Sudan.
MATERIALS AND METHODS
Between June 2000 and March 2002, all individuals pre-
senting at the Sleeping Sickness Treatment Center (SSTC)
located in Kiri in Kajo-Keji County were screened for HAT
using a screening (passive) and diagnostic protocol described
elsewhere.
9 Active screening was carried out with two mobile
teams who systematically visited all villages since April 2001.
All individuals found with a positive CATT-P titer of 1:4
during active screening were referred to the SSTC laboratory
for further diagnostic procedures.
Serologically suspected individuals were defined as indi-
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313viduals with a positive CATT-P titer of 1/4 with no trypano-
somes found in the cervical lymph nodes, blood (by the quan-
titative buffy coat technique or the hematocrit centrifugation
technique), or CSF (after double centrifugation), and a CSF
cell count 20/mm
3. Using the same plasma sample, a serial
two-fold dilution in CATT buffer up to a titer of 1:32 was
performed for all serologically suspected individuals between
June 2000 and March 2002, and the end-dilution titer was
recorded. All serologically suspected individuals were then
discharged from the SSTC laboratory and were requested to
come back for control visits after 3, 6, and 12 months. The
screening and diagnostic algorithm, as performed during the
initial evaluation,
9 was repeated at each control visit. Indi-
viduals who did not attend follow-up were traced at home by
locally trained Sleeping Sickness Assistants. Vehicle transport
was not provided because of logistic constraints. The Ethical
Review Board of Médecins Sans Frontières did not require
formal ethical review because the analysis was performed on
data routinely collected during the program.
Data collection. All sociodemographic and laboratory data,
including the results of the CATT-P end-dilution titer and the
laboratory results of the follow-up visits, were entered into
YoTryp, a Microsoft Access-based software (Microsoft, Red-
mond, WA) specifically designed for the program. In March
2003, all data was transferred onto SPSS version 11.0 statis-
tical software (SPSS, Inc., Chicago, IL) and analyzed.
Statistical analysis. Descriptive statistical analysis of socio-
demographic characteristics and laboratory test results at
screening of all serologically suspected individuals were per-
formed using frequency tables. All subjects with at least one
follow-up and the respective outcome were selected to calcu-
late the incidence of HAT, using the number of HAT cases
detected during follow-up as the numerator and the total per-
son-year as the denominator. To assess whether selection bias
occurred, sociodemographic characteristics and laboratory
test results at screening of subjects with at least one follow-up
were compared with those lost to follow-up, using cross-
tabulations and chi-square tests. To study the association be-
tween laboratory test results at screening and the risk of de-
veloping HAT during follow-up, we calculated the incidence
of HAT across four levels of CATT end-dilution serologic
results (1:4, 1:8, 1:16, and 1:32) and three levels of CSF cell
counts (0–5, 6–10, and 11–20) and the corresponding relative
risks. Cox models were used to calculate relative risks ad-
justed for other significant factors and cumulative hazard over
time of follow-up.
RESULTS
Between June 2000 and March 2002, 1,658 patients were
diagnosed with HAT (740 with stage 1 disease and 918 with
stage 2 disease) in the Kiri SSTC, while 2,355 individuals were
defined as serologically suspected. The CATT-P end-dilution
titer was determined in 2,274 of these 2,355 individuals
(97%): the end-dilution titer was 1:4 in 1,086 (48%), 1:8 in 761
(33%), 1:16 in 264 (12%), and 1:32 in 163 (7%). The CATT-P
end-dilution titer was not determined in 84 individuals (3%),
who were therefore excluded from further analysis. The so-
ciodemographic and laboratory characteristics of the 2,274
serologically suspected individuals included in the analysis are
shown in Table 1.
The follow-up attendance of the serologically suspected in-
dividuals was low and decreased over time: 553 individuals
(24%) were controlled at 3 months, 255 (11%) at 6 months,
and 92 (4%) at 12 months. A total of 749 individuals (33%)
were controlled at least once during follow-up. When com-
pared with the 1,525 individuals who were lost to follow-up,
these 749 individuals had a similar age, sex, CATT end-
dilution titer distribution, and CSF cell count, but were sta-
tistically (P < 0.05) more likely to be displaced Sudanese, to
come from the Bamurye camp, and to be detected by passive
screening (Table 1).
Human African trypanosomiasis was diagnosed in 64 sero-
logically suspected individuals during follow-up: 28 patients
(44%) with first-stage illness and 36 patients (56%) with sec-
ond-stage (or neurologic stage) illness. This represented 4%
(64 of 1,658) of all patients diagnosed with HAT in the Kiri
SSTC during the same period, 3% (64 of 2,274) of all indi-
viduals initially defined as serologically suspected, and 9%
(64 of 749) of those who attended at least one follow-up.
Predictors of a diagnosis of HAT during follow-up of se-
rologically suspected patients. Among the 749 serologically
suspected individuals who were controlled at least once dur-
ing follow-up, the sociodemographic characteristics and mode
of screening of the 64 individuals diagnosed with HAT during
follow-up were similar to those of the other 685 individuals.
The proportion of serologically suspected individuals eventu-
ally diagnosed with HAT increased with higher initial
CATT-P end-dilution titers (5%, 6.7%, 23.3%, and 19.6% for
1:4, 1:8, 1:16, and 1:32 titers, respectively) and with higher
initial CSF cell counts (7.3%, 16.7%, and 34.8% for 0–5, 6–10,
and 11–20 cells, respectively). Of the 64 HAT cases, 29 (45%)
patients had an initial CATT end-titer of 1:16 or 1:32, while 8
(13%) patients (including 7 with second-stage illness) had an
initial CSF cell counts of 11–20 cells.
The 749 serologically suspected individuals were followed
for a total of 129,201 days. The overall risk/person-year of
being diagnosed with HAT during follow-up was 18.1% and
increased for higher CATT-P dilutions and higher CSF cell
counts (Table 2). The risk was significantly higher in individu-
als with a CATT end-dilution titer  1/16 (Figure 1A) and in
individuals with a CSF cell count of 11–20 (Figure 1B). This
difference remained significant after adjustment for age, sex,
mode of screening, CSF cell count, and CATT end-dilution
titer. The combination of a CATT titer  1/16 and a CSF cell
count of 11–20 had an additive effect on the cumulative risk,
but this was found in only four individuals.
DISCUSSION
Because of the insufficient sensitivity of the current para-
sitologic field techniques and the limited specificity of the
CATT-WB and CATT-P 1/4,
4 many African patients infected
with T. b. gambiense go home undetected and untreated after
completion of investigations. This situation is unsatisfactory
not only for the infected individual, who will be more likely to
be diagnosed at a later stage or simply die at home, but also
for the community. Indeed, these individuals might maintain
the human reservoir of the parasite and contribute to further
transmission of the disease in the community. A possible ap-
proach is to follow-up and re-examine all serologically sus-
pected individuals at regular intervals to detect and treat
CHAPPUIS AND OTHERS 314those with a parasitologic confirmation during follow-up. Un-
fortunately, this strategy is very difficult to implement in the
field and its effectiveness is low, as shown in our program in
Kajo-Keji County in southern Sudan. Despite an effective
team of 30 community-based sleeping sickness assistants, all
well-motivated and regularly paid, the follow-up attendance
of serologically suspected individuals and the overall yield of
this strategy remained low.
Therefore, the early identification of serologically sus-
pected individuals likely to be infected with T. b. gambiense
TABLE 2
Risk of developing human African trypanosomiasis according to CATT end dilution titer and CSF cell count at screening in 749 serologically
suspected patients in Kajo-Keji county, southern Sudan*
Parameter
No. of cases of HAT
diagnosed
No. serologically
suspected Total days of follow-up
Risk/100
person-years
Relative risk
(95% CI)
Adjusted
relative risk
(95% CI)†
CATT end dilution titer
1:4 18 364 63,524 10.4 1.0 1.0
1:8 17 253 44,868 13.8 1.3 (0.7–2.5) 1.1 (0.5–2.1)
1:16 20 86 13,859 52.7 5.1 (2.6–9.5) 4.4 (2.3–8.4)
1:32 9 46 6,950 47.3 4.6 (2.0–9.8) 4.1 (1.8–9.4)
CSF cell count‡
0–5 50 685 118,086 15.5 1.0 1.0
6–10 6 36 5,884 37.3 2.4 (1.0–5.5) 2.0 (0.8–4.7)
11–20 8 23 3,836 76.2 4.9 (2.3–10.5) 4.4 (1.9–9.8)
Combination‡
CATT 1:4–1:8 and cells 0–10 31 598 105,718 10.7 1.0 1.0
CATT 1:16–1:32 and cells 0–10 25 123 19,647 46.5 4.3 (2.5–7.3) 4.5 (2.6–7.8)
CATT 1:4–1:8 and cells 11–20 4 15 2,674 54.7 5.1 (1.8–14.9) 5.0 (1.7–14.2)
CATT 1:16–1:32 and cells 11–20 4 8 1,162 125.7 11.7 (4.1–33.2) 15.5 (4.9–49.7)
* CATT  card agglutination test for trypanosomiasis test; CSF  cerebrospinal fluid; CI  confidence interval.
† All relative risk adjusted for age, sex, mode of screening, CATT end dilution titer, and CSF cell count.
‡ Five missing values.
TABLE 1
Sociodemographic characteristics and laboratory test results for African trypanomiasis at screening at 2,274 serologically suspect individuals, 749
individuals with at least one follow-up, and 1,525 individuals lost to follow-up in Kajo-Keji County, southern Sudan*
Characteristics
All serologically suspected
no. (%)
1 Control visit during follow-up
no. (%)
Lost to follow-up
no. (%) P†
Sex 0.97
Male 994 (44) 327 (44) 667 (44)
Female 1,280 (56) 422 (56) 858 (56)
Age (years) 0.21
0–4 82 (4) 20 (3) 62 (4)
5–14 612 (27) 209 (28) 403 (26)
>14 1,580 (70) 520 (69) 1,060 (70)
Status <0.001
Kajo-Keji resident 1,521 (67) 448 (60) 1,073 (70)
Sudanese from displaced camp 686 (30) 279 (37) 407 (27)
Non-Kajo-Keji residents 67 (3) 22 (3) 45 (3)
Payam of residence <0.001
Bamurye 570 (25) 260 (35) 310 (20)
Kangapo 1 466 (20) 139 (19) 327 (21)
Kangapo 2 921 (41) 220 (29) 701 (46)
Lirye 111 (5) 54 (7) 57 (4)
Livolo 105 (5) 43 (6) 62 (4)
Lobonok/Ngepo 37 (2) 15 (2) 22 (2)
Other county or Uganda 64 (3) 18 (2) 46 (3)
Mode of screening <0.001
Passive 1,360 (60) 539 (72) 821 (54)
Active 914 (40) 210 (28) 704 (46)
CATT end dilution 0.60
1:4 1,086 (48) 364 (49) 722 (47)
1:8 761 (33) 253 (34) 508 (33)
1:16 264 (12) 86 (11) 178 (12)
1:32 163 (7) 46 (6) 117 (8)
CSF cells‡ 0.10
0–5 2,104 (93) 683 (92) 1,421 (94)
6–10 105 (5) 35 (5) 70 (5)
11–20 49 (2) 23 (3) 26 (2)
* CATT  card agglutination test for trypanosomiasis; CSF  cerebrospinal fluid.
† by Pearson chi square test.
‡ Sixteen missing values.
PREDICTORS OF SLEEPING SICKNESS IN SUDAN 315would be very useful. In this study, we analyzed the initial
CATT end-dilution titers and the CSF cell counts of all sero-
logically suspected individuals (n  749) examined at least
once during follow-up. We found that individuals with a
CATT end-dilution titer of 1:16 or 1:32 had a higher risk of
being diagnosed with HAT during follow-up (risk for 100
person-years  53% and 47%, respectively), a significantly
higher risk (adjusted relative risk [RR]  4.4 and 4.1, respec-
tively) than individuals with a CATT end-dilution titer of 1:4
(risk for 100 person-years  10%). Similar findings have been
reported by Simarro and others in a smaller study in Angola.
7
If the 132 individuals with a CATT titer 1/16 had been
treated after initial evaluation, 29 (22%) individuals subse-
quently diagnosed with HAT would have been treated and
cured (provided that treatment was 100% efficient). How-
ever, 103 (78%) individuals would have been treated in ex-
cess. The PPV of a CATT titer 1/16, like any other diag-
nostic test, depends on the prevalence of the disease in the
tested population. The PPV was moderate (22%) in Kajo-
Keji, where the mean prevalence of HAT found during active
screening sessions was 1%, but was higher (52%) in the study
by Simarro and others in Angola, in which the prevalence of
HAT in the studied focus was 1.9%.
7 This concept is crucial
for policy makers and it would be extremely useful in the
future to gather and analyze all published and unpublished
data on that issue to determine a prevalence cut-off above
which treatment of individuals with a CATT titer 1/16 is
worthwhile. The decision should also depend on other factors
such as the availability and cost of treatment, the capacity to
perform repeated active screening sessions (potentially lim-
ited by geographic, safety, time, and/or transport constraints),
and the feasibility and expected effectiveness of a follow-up
strategy.
As suggested by Simarro and others, pentamidine is the
only therapeutic option for treating individuals with a CATT
titer 1/16.
7 Lumbar puncture should be performed in these
individuals to rule out second-stage illness (presence of try-
panosomes and/or >20 cells in the CSF). Despite the painful
daily intramuscular injections and the possible occurrence of
side effects such as hypoglycemia and hypotension, pentam-
idine therapy is relatively short (seven days) and very safe. In
Kajo-Keji, only 2 of more than 2,000 patients treated with
pentamidine died during treatment, and this was due to non–
drug-related causes. Pentamidine would not only be very ef-
ficient in treating undiagnosed first-stage patients (CSF cell
counts  0–5 cells), who would represent the highest propor-
tion of individuals (92% in Kajo-Keji), but would also have
some degree of efficiency in undiagnosed early second-stage
patients (CSF cell counts  6–20 cells).
10,11 Ongoing separate
studies are currently assessing the efficacy of a shortened
schedule (three days) of pentamidine and an oral drug, DB
289, for the treatment of first-stage HAT. The availability of
an oral treatment or, to a lesser extent, a shorter parenteral
treatment would greatly facilitate the treatment of both first-
stage and serologically suspected patients in the field.
An initial CSF cell count of 11–20 was also found to be a
strong risk factor for serologically suspected individuals diag-
nosed with HAT during follow-up with a risk for 100 person-
years of 76% and an adjusted RR of 4.4 compared with in-
dividuals with 0–5 cells in the CSF. However, this risk factor
was only found in 8 (13%) individuals diagnosed with HAT
during follow-up, all but one with second-stage disease. If one
considers the high toxicity of melarsoprol and the compli-
cated schedule of eflornithine (14 days of 4 daily slow infu-
sions), the only two drugs currently registered for the treat-
ment of second-stage illness, their use should be restricted to
confirmed cases.
Our study had one main potential limitation. The extrapo-
lation of our results to the whole population of serologically
suspected individuals could be limited by the low attendance
rate obtained during follow-up. Individuals with an unknown
outcome (lost to follow-up) had a significantly different sta-
tus, location of residence, and mode of screening, but had
comparable CATT-P end-dilution titers and CSF cell counts,
the only factors found to be associated with a higher risk of
HAT. The attendance of follow-up visits was therefore influ-
enced more by factors such as distance, mobility and motiva-
tion. Therefore, we believe that it is reasonable to extrapolate
FIGURE 1. Cumulative risk of being diagnosed with human African trypanosomiasis (HAT) in relation to A, the card agglutination trypa-
nosomiasis test (CATT)–plasma end-dilution titer and B, the cerebrospinal fluid (CSF) cell count during a one-year follow-up of 749 serologically
suspected individuals in Kajo-Keji County in southern Sudan.
CHAPPUIS AND OTHERS 316our results to the whole population of serologically suspected
individuals diagnosed during the study period in Kajo-Keji.
In conclusion, we showed that the follow-up of serologi-
cally suspected individuals had a low effectiveness and yield
in a field setting such as southern Sudan. We identified a
CATT-P titer 1/16 as a useful predictor of HAT in this
population. We suggest that treatment of these individuals
with pentamidine is worthwhile, both on an individual and
public health basis, if the prevalence of HAT in the popula-
tion investigated is sufficiently high. Which cut-off of preva-
lence to choose remains an open question. It should probably
not be less than 1% and the decision should be tempered by
other factors such as distance to the treatment center and
means of transportation. Based on these results, all serologi-
cally suspected individuals with a CATT-P titer 1/16 diag-
nosed in Kajo-Keji County during passive screening or first-
round active screening (the settings where the highest preva-
lence of HAT is found) since March 2002 have received
treatment with pentamidine.
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